Jerome Nicol
Overview
Explore the profile of Jerome Nicol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barre T, Parlati L, Bourliere M, Ramier C, Marcellin F, Protopopescu C, et al.
J Viral Hepat
. 2024 Sep;
31(12):830-846.
PMID: 39252600
Although Hepatitis C virus (HCV) infection can be cured with direct-acting antivirals (DAA), some cured patients face a serious risk of advanced liver damage and early mortality. In order to...
2.
Barre T, Bourliere M, Parlati L, Ramier C, Marcellin F, Protopopescu C, et al.
Drug Alcohol Rev
. 2023 Dec;
43(3):718-731.
PMID: 38133601
Introduction: The risk of mortality in people with a history of injection drug use (PHID) is high, as is the prevalence of hepatitis C virus (HCV) infection. Although direct-acting antivirals...
3.
Lam L, Fontaine H, Lapidus N, Bellet J, Lusivika-Nzinga C, Nicol J, et al.
J Viral Hepat
. 2022 Dec;
30(3):232-241.
PMID: 36529681
The validity of algorithms for identifying patients with chronic hepatitis B or C virus (HBV or HCV) infection in claims databases has been little explored. The performance of 15 algorithms...
4.
Long-lasting Symptoms After an Acute COVID-19 Infection and Factors Associated With Their Resolution
Robineau O, Zins M, Touvier M, Wiernik E, Lemogne C, de Lamballerie X, et al.
JAMA Netw Open
. 2022 Nov;
5(11):e2240985.
PMID: 36350653
Importance: Persistent symptoms after SARS-CoV-2 infection are an emerging public health problem. The duration of these symptoms remains poorly documented. Objective: To describe the temporal dynamics of persistent symptoms after...
5.
Carrat F, Saba Villarroel P, Lapidus N, Fourie T, Blanche H, Dorival C, et al.
Sci Rep
. 2022 Jun;
12(1):9405.
PMID: 35672373
No abstract available.
6.
Carrat F, Saba Villarroel P, Lapidus N, Fourie T, Blanche H, Dorival C, et al.
Sci Rep
. 2022 May;
12(1):8622.
PMID: 35597776
Assessment of the intensity, dynamics and determinants of the antibody response after SARS-CoV-2 infection or vaccination in the general population is critical to guide vaccination policies. This study characterized the...
7.
Carrat F, de Lamballerie X, Rahib D, Blanche H, Lapidus N, Artaud F, et al.
Int J Epidemiol
. 2021 Aug;
50(5):1755.
PMID: 34453524
No abstract available.
8.
Carrat F, de Lamballerie X, Rahib D, Blanche H, Lapidus N, Artaud F, et al.
Int J Epidemiol
. 2021 Jul;
50(5):1458-1472.
PMID: 34293141
Background: We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the...
9.
Gaboriaud P, Ferte M, Arnold F, Leblond V, Nicol J, Debare H, et al.
Emerg Microbes Infect
. 2018 Mar;
7(1):22.
PMID: 29511157
The presence of specific antibodies against human polyomavirus 12, Saint Louis polyomavirus and New Jersey polyomavirus was investigated by using virus-like particle-based ELISAs with serum samples from 706 Italians aged...